Executive Summary: More than 80% of enterprise AI projects fail to deliver their intended business value, with many abandoned before production and others completed but underperforming. As AI investment accelerates, most enterprises are stuck at this stage: enthusiasm...
For life sciences leaders, the next inspection is more than a regulatory event — it is a real-time test of operational maturity. As agencies expand risk-based and digitally enabled oversight, readiness reflects whether an organization can sustain control across global...
Building a smarter maintenance model has become a strategic priority for regulated and asset-intensive organizations. Across several industries, leaders are under pressure to reduce downtime, extend asset life, safeguard quality and compliance, and make better use of...
For patients, a missing record is never just a data problem. It can mean retelling a medical history in an emergency, waiting for a discharge summary that has not reached the next provider, or undergoing a repeat test because the last result is trapped somewhere else....
Data center modernization has become a strategic priority as AI accelerates demand for power, cooling, and faster capacity deployment. The goal isn’t simply to add capacity, though; it is to create an environment that supports growth without introducing energy risk,...
Artificial intelligence is advancing faster than many organizations can absorb it. New tools can summarize information, generate content, automate workflows, and support complex decisions. But AI implementation and AI adoption are not the same. Implementation makes...
Drug discovery has always depended on high-stakes decisions with incomplete information, necessitating a faster, smarter model. Today, artificial intelligence is giving life sciences organizations a more powerful way to connect biological, chemical, clinical, and...
Compliance has become a defining factor in an organization's ability to transform with confidence. In regulated industries, keeping pace through manual reviews and disconnected controls is no longer enough. Compliance now sits at the center of digital reinvention,...
Rare disease clinical research is uniquely challenging, as patient populations are small and geographically dispersed, and disease courses can be highly variable. Additionally, traditional fixed trial designs often struggle to deliver timely, decision-ready evidence....
